We use linguistics

to characterize

patient health.


Our assays fingerprint abnormalities early,

before full-blown symptoms appear


We are at the leading edge of

Linguistics research


Analyzing Language, Improving Health

About us

We empower patients with tools to measure their overall health through collecting and analyzing speech samples. By fingerprinting health abnormalities early, we equip patients and physicians with insight to prevent symptoms from worsening. In this way, we strive to be the world's leading platform company to advance linguistics as a tool to characterize various health conditions.
For patients

Analyze your own speech patterns to measure your overall health and detect health abnormalities.

For Physicians

Use syntactic and semantic information as an aid to characterize patient symptoms.

For Pharma

Deploy linguistic biomarker assays to track the efficacy of drugs throughout clinical studies.

For Researchers

Mine data and co-develop new patient linguistic analysis protocols using our open APIs.

We believe the next-generation of medicine will be personalized, quality-driven, and focused on prevention. We place your health at your fingertips through our linguistic biomarker assays.

Areas of Focus


Many individuals that suffer from strokes have deficits in language, such as the inability to find the right words (aphasia). Our software can help to characterize the extent of injury and aid in stroke recovery.

Fatigue Detection

Few metrics are available to characterize fatigue. Our algorithms over time can characterize the extent to which someone is awake, which is important for a variety of jobs.

Alzheimer's Disease

Alzheimer's disease (AD) is a progressive degenerative disease characterized by a gradual decline in memory. Our algorithms can characterize memory decline as AD progresses.

Pain Detection

Pain is often measured through subjective rating scales. We use language in tandem with these scales to better quantify the extent of pain in patients (e.g. arthritis).


Children that have autism often exhibit distinct variations in language, such as mixing up pronouns or interpreting rhetorical statements literally. Our algorithms can thus help characterize the symptoms of autism and personalize learning around patient strengths.

Bipolar II Disorder

Bipolar II disorder is characterized fluctuating periods of hypomania and depression. These fluctuations often lead to language variations and changes the pace which words are spoken and thoughts are formed. Our algorithms can thus act as a biometric to characterize changes in bipolar II disorder.


Individuals who develop schizophrenia often have a lead-up period called the "prodrome" marked by thought broadcasting and odd use of language. Our algorithms, combined with traditional psychotic rating scales, can characterize these changes and predict which individuals will have onset psychosis and which will not.

Anxiety & Depression

Our algorithms use sentiment analysis to detect anxiety and the extent to which you are depressed. This characterization, when used in parallel to traditional depression and anxiety inventories, can lead to prompt medical treatment, as necessary.

Our Team

Jim Schwoebel
Chief Executive Officer

Jim has started, managed, and grown companies across multiple sizes, stages, and market sectors, taking the roles of CEO, CTO,…

Drew Morris
Chief Technology Officer

Drew Morris is a technology consultant based out of the Atlanta area with a strong background in developing applications…

Kerry Byler
Chief Financial Officer

As CFO, Kerry brings NeuroLex more than 15 years of assisting high growth companies in their strategic planning, fundraising,…

James Christopher Fairey
Chief Audio Officer

James is a systems and methods patented inventor/producer with over 30 years of experience in audio recording and applied…

Contact Us

We are actively seeking investors, partnerships, and R&D pilots. Let us know how we can work together!


NeuroLex Diagnostics
Telephone: 412-613-0772
Atlanta <> Boston <> New York <> San Francisco.

DISCLAIMER: Our software suite has not been evaluated by the Food and Drug Administration and is not intended to diagnose, treat, cure or prevent any disease.


Copyright © 2016, NeuroLex Diagnostics